Mometasone Furoate Cream

This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition

Issued and maintained by the United States Pharmacopeial Convention (USP)

DOWNLOAD PDF HERE

1 DEFINITION

Mometasone Furoate Cream is Mometasone Furoate in a suitable cream base. It contains NLT 90.0% and NMT 110.0% of the labeled amount of mometasone furoate (C₂₇H₃₀Cl₂O₆).

2 IDENTIFICATION

2.1 A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, both relative to the internal standard, as obtained in the Assay.

2.2 B. Thin-Layer Chromatographic Identification Test 〈201〉

Standard solution: 0.2 mg/mL of USP Mometasone Furoate RS in acetonitrile

Sample solution: 0.2 mg/mL of mometasone furoate from Cream in acetonitrile

Developing solvent system: Chloroform and ethyl acetate (3:1)

Acceptance criteria: The Rf value of the principal spot of the Sample solution corresponds to that of the Standard solution.

3 ASSAY

3.1 Procedure

[Note-Protect from light.]

Diluent A: Tetrahydrofuran and glacial acetic acid (100:1)

Diluent B: Acetonitrile, water, and glacial acetic acid (50:50:1)

Solution A: Water

Solution B: Acetonitrile

Mobile phase: See Table 1.

Table 1

Internal standard solution: 1.4 mg/mL of diethyl phthalate in acetonitrile

Standard stock solution: 0.2 mg/mL of USP Mometasone Furoate RS in Diluent A

Standard solution: 0.05 mg/mL of mometasone furoate and 0.35 mg/mL of diethyl phthalate from equal quantities of the Standard stock solution and the Internal standard solution, in Diluent B

Sample solution: Transfer a portion of Cream, equivalent to 1.0 mg of mometasone furoate, to a 50-mL, screw-capped centrifuge tube. Add 5.0 mL of Diluent A and a few glass beads, and mix on a vortex mixer. Add 5.0 mL of Internal standard solution, and mix. Add 10.0 mL of Diluent B, mix on a vortex mixer for 1 min, and centrifuge for 10 min. Pass the aqueous phase through a polypropylene filter of 0.2-µm pore size, discarding the first 1–2 mL of filtrate.

Chromatographic system

• (See Chromatography 〈621〉, System Suitability.)
• Mode: LC
• Detector: UV 254 nm
• Column: 4.6-mm × 25-cm; 5-µm packing L60
• Flow rate: 2 mL/min
• Injection size: 20 µL

System suitability

• Sample: Standard solution
• [Note-The relative retention times for diethyl phthalate and mometasone furoate are 0.4 and 1.0, respectively.]
• Suitability requirements
• Tailing factor: NMT 1.5 for the mometasone furoate peak
• Relative standard deviation: NMT 2.0%

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of mometasone furoate (C₂₇H₃₀Cl₂O₆) in the portion of Cream taken:

Result = (Rᵤ/Rₛ) × (Cₛ/Cᵤ) × 100

Rᵤ = ratio of the mometasone furoate peak response to the diethyl phthalate peak response from the Sample solution

Rₛ = ratio of the mometasone furoate peak response to the diethyl phthalate peak response from the Standard solution

Cₛ = concentration of USP Mometasone Furoate RS in the Standard solution (mg/mL)

Cᵤ = nominal concentration of mometasone furoate in the Sample solution (mg/mL)

Acceptance criteria: 90.0%–110.0%

4 PERFORMANCE TESTS

Minimum Fill 〈755〉: Meets the requirements

5 IMPURITIES

5.1 Organic Impurities

[Note-Protect from light.]

Diluent A, Solution A, Solution B, Mobile phase, and Standard stock solution: Prepare as directed in the Assay.

Diluent C: Acetonitrile, water, and glacial acetic acid (30:70:1)

System suitability solution: 0.1 µg/mL of USP Mometasone Furoate RS from Standard stock solution in Diluent C

Blank solution: Diluent C and Diluent A (3:1)

Sample solution: Transfer a portion of Cream, equivalent to 2.0 mg of mometasone furoate, to a 50-mL, screw-capped centrifuge tube. Add 5.0 mL of Diluent A and a few glass beads, and mix on a vortex mixer. Add 15.0 mL of Diluent C, and mix. Centrifuge for 10 min. Pass the aqueous phase through a 0.2-µm polypropylene filter, discarding the first 1–2 mL of filtrate.

Chromatographic system

• (See Chromatography 〈621〉, System Suitability.)
• Mode: LC
• Detector: UV 254 nm
• Column: 4.6-mm × 25-cm; 5-µm packing L60
• Column temperature: 25 ± 5°
• Flow rate: 2 mL/min
• Injection size: 50 µL
• System suitability
• Sample: System suitability solution
• Suitability requirements
• Relative standard deviation: NMT 10%

Analysis

Samples: System suitability solution, Blank solution, and Sample solution

[Note-Exclude any peak areas less than those from the System suitability solution. Also exclude any peaks with the same retention time as that observed in the Blank solution. Any peaks having a relative retention time of about 1.04 or 1.13 are controlled in the Mometasone Furoate monograph and, therefore, are not included in the total specified and unspecified impurities limit.]

Calculate the percentage of each impurity in the portion of Cream taken:

Result = (r_U/r_T) × 100

r_U = peak response of each impurity from the Sample solution

r_T = sum of all the peak responses from the Sample solution

Acceptance criteria: See Table 2.

Table 2

6 SPECIFIC TESTS

Microbial Enumeration Tests 〈61〉 and Tests for Specified Microorganisms 〈62〉: It meets the requirements of the tests for absence of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Salmonella species.

7 ADDITIONAL REQUIREMENTS

Packaging and Storage: Preserve in well-closed containers, and store at controlled room temperature.

USP Reference Standards 〈11〉

USP Mometasone Furoate RS